FDA notifications. Accelerated approval of tipranavir.
D000328:Adult; D017326:Clinical Trials, Phase III as Topic; D018849:Controlled Clinical Trials as Topic; D004334:Drug Administration Schedule; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015497:HIV-1 / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D011753:Pyrones / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir